In Europe, six systemic therapies for AD have been approved: the biologics dupilumab (anti-interleukin-4 receptor [IL-4R]), tralokinumab (anti-IL-13), and lebrikizumab (anti-IL-13) and the oral Janus kinase (JAK) inhibitors (JAKis) targeting JAK1/2 (baricitinib) and JAK1 (upadacitinib and abrocitinib) [4]. This evidence concerns the gene JAK1 and Alzheimer disease.